Humana upped at UBS, execution cited

AudeLagorce

LONDON (MarketWatch) -- UBS upgraded health-care provider Humana Inc
HUM, +0.12%
to neutral from reduce and raised its price target to $48 from $46, saying the company has executed well on membership and cost issues. In addition, the broker told clients that with improved visibility on membership growth for 2006 and strong reported medical costs in the period, it is more comfortable with the company at its current valuation.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.